Unoprostone

Identification

Name
Unoprostone
Accession Number
DB06826
Type
Small Molecule
Groups
Approved, Investigational
Description

Unoprostone isopropyl is a prostaglandin analogue. Ophthalmic Solution 0.15% is a synthetic docosanoid. Unoprostone isopropyl has the chemical name isopropyl (+)-(Z)-7-[(1R,2R,3R,5S)-3,5 dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-heptenoate. The main indication of Unoprostane is treatment of glucoma.

Structure
Thumb
Synonyms
  • 13,14-dihydro-15-keto-20-ethyl PGF2α
External IDs
UF 021 / UF-021 / UF021
Product Ingredients
IngredientUNIICASInChI Key
Unoprostone isopropyl5M161S5O5P120373-24-2XXUPXHKCPIKWLR-JHUOEJJVSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ResculaSolution0.15 %OphthalmicNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc2002-05-272006-01-18Canada
ResculaSolution / drops1.5 mg/mLOphthalmicSucampo Pharma Americas, Llc2013-01-072017-12-22Us
Categories
UNII
6X4F561V3W
CAS number
120373-36-6
Weight
Average: 382.541
Monoisotopic: 382.271924324
Chemical Formula
C22H38O5
InChI Key
TVHAZVBUYQMHBC-SNHXEXRGSA-N
InChI
InChI=1S/C22H38O5/c1-2-3-4-5-8-11-17(23)14-15-19-18(20(24)16-21(19)25)12-9-6-7-10-13-22(26)27/h6,9,18-21,24-25H,2-5,7-8,10-16H2,1H3,(H,26,27)/b9-6-/t18-,19-,20+,21-/m1/s1
IUPAC Name
(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoic acid
SMILES
CCCCCCCC(=O)CC[[email protected]]1[[email protected]](O)C[[email protected]](O)[[email protected]@H]1C\C=C/CCCC(O)=O

Pharmacology

Indication

For the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.

Structured Indications
Pharmacodynamics

Unoprostone will begin to reduce IOP 30 minutes after ocular instillation.

Mechanism of action

Unoprostone is believed to reduce elevated intraocular pressure (IOP), by increasing the outflow of aqueous humor. The mechanism of action for the IOP-lowering effect of unoprostone is controversial. Early studies showed that unoprostone increases aqueous humor outflow through the uveoscleral pathway similar to the 20-carbon prostaglandin analogs, such as latanoprost.8 More recent evidence, however, shows that it may work, at least in part, through stimulation of Ca2+-activated BK and CIC-2 type channels, leading to increased trabecular meshwork outflow.

Absorption

After application to the eye, unoprostone isopropyl is absorbed through the cornea and conjunctival epithelium where it is hydrolyzed by esterases to unoprostone free acid. mean peak unoprostone free acid plasma concentration was <1.5 ng/mL and dro pped below the lower limit of quantitation (<0.250 ng/mL) 1 hour following instillation, indicating low systemic absorption and rapid plasma excretion.

Volume of distribution

Intended for local use only, very low systemic absorption.

Protein binding

Intended for local use only, very low systemic absorption.

Metabolism

After ocular application, unoprostone isopropyl is hydrolyzed by esterases in the cornea to its biological active metabolite, unoprostone free acid. Unoprostone free acid is then metabolized to several inactive metabolites with lower molecular weight and increased polarity via ε- or β-oxidation. No secondary conjugation is found and no significant effect on hepatic microsomal enzyme activity has been observed.

Route of elimination

Elimination of unoprostone free acid from human plasma is rapid. Plasma levels of unoprostone free acid dropped below the lower limit of quantitation ( < 0.25 ng/mL) 1 hour following ocular instillation. Urinary elimination is the predominant elimination route.

Half life

Half-life of Unoprostone is 14 minutes.

Clearance

Intended for local use only, very low systemic absorption.

Toxicity

LD50 in rats: 1g/Kg (subcutaneous), 93500 µg/Kg (IV).

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with (4R)-limonene.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Unoprostone.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Unoprostone.Approved, Investigational
AceclofenacThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Adapalene.Approved
AlclofenacThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlfuzosinAlfuzosin may increase the hypotensive activities of Unoprostone.Approved, Investigational
AliskirenUnoprostone may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Alminoprofen.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Unoprostone.Approved, Withdrawn
AmbrisentanUnoprostone may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineUnoprostone may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Unoprostone.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Unoprostone.Approved, Illicit, Investigational
AndrographolideThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Andrographolide.Investigational
AnisodamineThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Anisodamine.Investigational
AntipyrineThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Antipyrine.Approved, Investigational
ApocyninThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Apocynin.Investigational
ApremilastThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Apremilast.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Unoprostone.Approved
AvanafilAvanafil may increase the antihypertensive activities of Unoprostone.Approved
AzapropazoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Azelastine.Approved
BalsalazideThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Balsalazide.Approved, Investigational
BarnidipineUnoprostone may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Unoprostone.Approved, Investigational
BendazacThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Unoprostone.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Unoprostone.Withdrawn
BenorilateThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Benzydamine.Approved
BepridilBepridil may increase the hypotensive activities of Unoprostone.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Unoprostone.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Unoprostone.Approved
BevoniumThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Unoprostone.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Unoprostone.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Unoprostone.Approved
BosentanBosentan may increase the hypotensive activities of Unoprostone.Approved, Investigational
BQ-123Unoprostone may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Unoprostone.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Unoprostone.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Unoprostone.Experimental
BromfenacThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Bucillamine.Investigational
BufexamacThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Bufexamac.Approved, Experimental
BumadizoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Bumadizone.Experimental
BupranololUnoprostone may increase the hypotensive activities of Bupranolol.Approved
CadralazineCadralazine may increase the hypotensive activities of Unoprostone.Experimental
CafedrineUnoprostone may increase the hypotensive activities of Cafedrine.Investigational
CandesartanUnoprostone may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Unoprostone.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Unoprostone.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Unoprostone.Approved
Carbaspirin calciumThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Unoprostone.Withdrawn
CarprofenThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Unoprostone.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Unoprostone.Approved, Investigational
CastanospermineThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Unoprostone.Approved, Investigational
ChloroquineThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Unoprostone.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Unoprostone.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CicletanineUnoprostone may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Unoprostone.Approved
ClonidineClonidine may increase the hypotensive activities of Unoprostone.Approved
ClonixinThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Clonixin.Approved
CloranololUnoprostone may increase the hypotensive activities of Cloranolol.Experimental
CryptenamineCryptenamine may increase the hypotensive activities of Unoprostone.Approved
CurcuminThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Curcumin.Approved, Investigational
CyclopenthiazideUnoprostone may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Unoprostone.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Unoprostone.Approved, Investigational
DelaprilUnoprostone may increase the hypotensive activities of Delapril.Experimental
DeserpidineUnoprostone may increase the hypotensive activities of Deserpidine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Unoprostone.Approved
DiclofenacThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Unoprostone.Investigational
DifenpiramideThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Difenpiramide.Experimental
DiflunisalThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Diflunisal.Approved, Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Unoprostone.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Unoprostone.Approved, Investigational
DorzolamideDorzolamide may increase the hypotensive activities of Unoprostone.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Unoprostone.Approved
DroxicamThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Droxicam.Withdrawn
DuvelisibThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Unoprostone can be decreased when used in combination with E-6201.Investigational
EfonidipineUnoprostone may increase the hypotensive activities of Efonidipine.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Unoprostone.Approved, Vet Approved
EnalaprilatUnoprostone may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Unoprostone.Experimental
EpanololUnoprostone may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Epirizole.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Unoprostone.Approved
EprosartanEprosartan may increase the hypotensive activities of Unoprostone.Approved
EtanerceptThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Etanercept.Approved, Investigational
EthenzamideThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Ethenzamide.Experimental
EtodolacThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoricoxibThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Etoricoxib.Approved, Investigational
Evening primrose oilThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Evening primrose oil.Approved, Investigational
ExisulindThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Exisulind.Investigational
FelbinacThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Felbinac.Experimental
FelodipineFelodipine may increase the hypotensive activities of Unoprostone.Approved, Investigational
FenbufenThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Unoprostone.Approved
FenoprofenThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Fenoprofen.Approved
FentiazacThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Ferulic acid.Experimental
FloctafenineThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FlunixinThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Flunoxaprofen.Experimental
FlurbiprofenThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Unoprostone.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Unoprostone.Approved, Investigational, Vet Approved
GuacetisalThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Unoprostone.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Unoprostone.Approved
GuanazodineUnoprostone may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Unoprostone.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Unoprostone.Approved, Investigational
GuanoclorUnoprostone may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzUnoprostone may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanUnoprostone may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Unoprostone.Experimental
HexamethoniumUnoprostone may increase the hypotensive activities of Hexamethonium.Experimental
HigenamineThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Unoprostone.Experimental
HydralazineHydralazine may increase the hypotensive activities of Unoprostone.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Unoprostone.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Unoprostone.Approved, Investigational
IbuprofenThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Icatibant.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Unoprostone.Approved, Investigational
ImidaprilUnoprostone may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Imidazole salicylate.Experimental
IndapamideIndapamide may increase the hypotensive activities of Unoprostone.Approved
IndenololUnoprostone may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Unoprostone.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Unoprostone.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Unoprostone.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Unoprostone.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Unoprostone.Approved
IsoxicamThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Unoprostone.Approved, Investigational
KebuzoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Unoprostone.Investigational
KetoprofenThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Unoprostone.Approved
LacidipineUnoprostone may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Unoprostone.Approved, Investigational
LeflunomideThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Unoprostone.Approved, Investigational
LinsidomineUnoprostone may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Unoprostone.Approved, Investigational
LisofyllineThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Lisofylline.Investigational
LofexidineLofexidine may increase the hypotensive activities of Unoprostone.Approved, Investigational
LonazolacThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Lornoxicam.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Unoprostone.Approved
LoxoprofenThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Loxoprofen.Approved, Investigational
LumiracoxibThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanUnoprostone may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineUnoprostone may increase the hypotensive activities of Manidipine.Approved, Investigational
MasoprocolThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Unoprostone.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Unoprostone.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Mefenamic acid.Approved
MeloxicamThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MethoserpidineUnoprostone may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaMethyldopa may increase the hypotensive activities of Unoprostone.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Unoprostone.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Unoprostone.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of Unoprostone.Approved
MetolazoneMetolazone may increase the hypotensive activities of Unoprostone.Approved
MetoprololMetoprolol may increase the hypotensive activities of Unoprostone.Approved, Investigational
MetyrosineUnoprostone may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Unoprostone.Investigational, Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Unoprostone.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Unoprostone.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Unoprostone.Investigational
MizoribineThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Unoprostone.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Unoprostone.Approved
MofebutazoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Unoprostone.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Unoprostone.Approved, Investigational
MuzolimineUnoprostone may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Nabumetone.Approved
NadololNadolol may increase the hypotensive activities of Unoprostone.Approved
NafamostatThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Naftifine.Approved
NaftopidilUnoprostone may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Naproxen.Approved, Vet Approved
NebivololNebivolol may increase the hypotensive activities of Unoprostone.Approved, Investigational
NepafenacThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Nepafenac.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Unoprostone.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Unoprostone.Approved, Investigational
NicorandilUnoprostone may increase the hypotensive activities of Nicorandil.Approved, Investigational
NifenazoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineUnoprostone may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Unoprostone.Approved, Investigational
NimesulideThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Unoprostone.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Unoprostone.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Unoprostone.Approved, Investigational
NitroaspirinThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Unoprostone.Approved, Investigational
ObinutuzumabUnoprostone may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Unoprostone.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Unoprostone.Approved, Investigational
OlopatadineThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Unoprostone.Investigational
OrgoteinThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Orgotein.Vet Approved
OxaprozinThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Oxaprozin.Approved
OxprenololOxprenolol may increase the hypotensive activities of Unoprostone.Approved
OxyphenbutazoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
ParecoxibThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Unoprostone.Approved
ParthenolideThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Parthenolide.Approved, Investigational
PenbutololPenbutolol may increase the hypotensive activities of Unoprostone.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of Unoprostone.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Unoprostone.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Unoprostone.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Unoprostone.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Unoprostone.Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Unoprostone.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Unoprostone.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Unoprostone.Approved
PhenylbutazoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Unoprostone.Approved
PindololPindolol may increase the hypotensive activities of Unoprostone.Approved, Investigational
PirfenidoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Unoprostone.Approved
PiroxicamThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Unoprostone.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Unoprostone.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Unoprostone.Approved
PranoprofenThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Unoprostone.Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Unoprostone.Approved, Investigational
ProglumetacinThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Propacetamol.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Unoprostone.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Proquazone.Experimental
PTC299The therapeutic efficacy of Unoprostone can be decreased when used in combination with PTC299.Investigational
QuinaprilQuinapril may increase the hypotensive activities of Unoprostone.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Unoprostone.Approved
RamiprilRamipril may increase the hypotensive activities of Unoprostone.Approved
RasagilineRasagiline may increase the hypotensive activities of Unoprostone.Approved
RemikirenRemikiren may increase the hypotensive activities of Unoprostone.Approved
RescinnamineUnoprostone may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Unoprostone.Approved, Investigational
ResveratrolThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Unoprostone.Approved, Investigational
RiociguatUnoprostone may increase the hypotensive activities of Riociguat.Approved
RituximabUnoprostone may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
SafrazineSafrazine may increase the hypotensive activities of Unoprostone.Withdrawn
SalicylamideThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Salsalate.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Unoprostone.Experimental
SelegilineSelegiline may increase the hypotensive activities of Unoprostone.Approved, Investigational, Vet Approved
SelexipagUnoprostone may increase the hypotensive activities of Selexipag.Approved
SemapimodThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Serrapeptase.Investigational
SildenafilSildenafil may increase the antihypertensive activities of Unoprostone.Approved, Investigational
SitaxentanUnoprostone may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilSpirapril may increase the hypotensive activities of Unoprostone.Approved
SRT501The therapeutic efficacy of Unoprostone can be decreased when used in combination with SRT501.Investigational
SulfasalazineThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Sulindac.Approved, Investigational
SuprofenThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Unoprostone.Approved, Investigational
TalinololUnoprostone may increase the hypotensive activities of Talinolol.Investigational
TarenflurbilThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tarenflurbil.Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Unoprostone.Approved, Investigational
TemocaprilUnoprostone may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tepoxalin.Vet Approved
TeriflunomideThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Teriflunomide.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Unoprostone.Approved, Investigational
TetrahydropalmatineUnoprostone may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineUnoprostone may increase the hypotensive activities of Theodrenaline.Investigational
Tiaprofenic acidThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneUnoprostone may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Unoprostone.Withdrawn
TimololTimolol may increase the hypotensive activities of Unoprostone.Approved
TinoridineThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tinoridine.Investigational
TolazolineTolazoline may increase the hypotensive activities of Unoprostone.Approved, Vet Approved
Tolfenamic AcidThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tolmetin.Approved
TolonidineUnoprostone may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Unoprostone.Approved
TorasemideTorasemide may increase the hypotensive activities of Unoprostone.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Unoprostone.Approved
TranilastThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Unoprostone.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Unoprostone.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Unoprostone.Approved, Investigational
TribenosideThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tribenoside.Experimental
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Unoprostone.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Unoprostone.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Unoprostone.Approved, Investigational
TriptolideThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Triptolide.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Unoprostone.Investigational
ValdecoxibThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Unoprostone.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Unoprostone.Approved
VincamineUnoprostone may increase the hypotensive activities of Vincamine.Experimental
VinpocetineUnoprostone may increase the hypotensive activities of Vinpocetine.Investigational
XipamideUnoprostone may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Unoprostone.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Unoprostone.Approved, Investigational, Vet Approved
ZaltoprofenThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilUnoprostone may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
Not Available

References

General References
  1. article [Link]
  2. Monogragh [Link]
External Links
PubChem Compound
5311236
PubChem Substance
347827802
ChemSpider
4470755
ChEBI
39455
ChEMBL
CHEMBL1201407
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Unoprostone
ATC Codes
S01EE02 — Unoprostone
FDA label
Download (36.9 KB)
MSDS
Download (32.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentDry Age-related Macular Degeneration1
3TerminatedTreatmentRetinitis Pigmentosa (RP)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionOphthalmic0.15 %
Solution / dropsOphthalmic1.5 mg/mL
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6458836No2001-07-092021-07-09Us
US6770675No1998-11-242018-11-24Us

Properties

State
Liquid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0306 mg/mLALOGPS
logP3.99ALOGPS
logP3.91ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)4.31ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity107.68 m3·mol-1ChemAxon
Polarizability45.47 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Eicosanoids
Direct Parent
Prostaglandins and related compounds
Alternative Parents
Long-chain fatty acids / Hydroxy fatty acids / Unsaturated fatty acids / Cyclopentanols / Ketones / Cyclic alcohols and derivatives / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
Substituents
Prostaglandin skeleton / Long-chain fatty acid / Hydroxy fatty acid / Cyclopentanol / Fatty acid / Unsaturated fatty acid / Cyclic alcohol / Ketone / Secondary alcohol / Carboxylic acid
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
oxo monocarboxylic acid, prostaglandins Falpha, ketone (CHEBI:39455) / Prostaglandins (LMFA03010204)

Drug created on September 14, 2010 10:21 / Updated on May 02, 2018 01:33